U.K. Launch Delays Under NICE Predicted By Rx Industry
Executive Summary
Pharmaceutical launches could be delayed by two or more years under the U.K.' s recently implemented National Institute for Clinical Excellence, Glaxo Wellcome Corporate Affairs Director and Association of the British Pharmaceutical Industry President Michael Bailey maintained at a London press conference April 7.
You may also be interested in...
U.K. Regulators To Consider FDA-Style Transparency
The U.K.' s Medicines Control Agency will consider the adoption of FDA-style transparency to communicate information about its activities more effectively, according to a five-year review of the agency conducted by the U.K. Department of Health.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011